Cleveland BioLabs, Inc. (NASDAQ:CBLI) has a beta value of 0.97 and has seen 4,642,587 shares traded in the recent trading session. The company, currently valued at $34.11 Million, closed the recent trade at $2.64 per share which meant it lost -$1.62 on the day or -38.03% during that session. The CBLI stock price is -89.39% off its 52-week high price of $5 and 81.06% above the 52-week low of $0.5. If we look at the company’s 10-day average daily trading volume, we find that it stood at 8.86 Million shares traded. The 3-month trading volume is 1.09 Million shares.

The consensus among analysts is that Cleveland BioLabs, Inc. (CBLI) is a Hold stock at the moment, with a recommendation rating of 0. None of the analysts rate the stock as a Sell, while none rate it as Overweight. 1 out of 1 have rated it as a Hold, with no one of them advising it as a Buy. None have rated the stock as Underweight.

Cleveland BioLabs, Inc. (NASDAQ:CBLI) trade information

Despite being -38.49% in the red today, the stock has traded in the green over the last five days, with the highest price hit on Friday, Jun 26 when the CBLI stock price touched $4.43-4 or saw a rise of 40.41%. Year-to-date, Cleveland BioLabs, Inc. shares have moved 338.54%, while the 5-day performance has seen it change 60%. Over the past 30 days, the shares of Cleveland BioLabs, Inc. (NASDAQ:CBLI) have changed 28.78%. Short interest in the company has seen 10.98 Million shares shorted with days to cover at 10.07.

Wall Street analysts have a consensus price target for the stock at $40, which means that the shares’ value could jump 1415.15% from current levels. The projected low price target is $40 while the price target rests at a high of $40. In that case, then, we find that the current price level is +1415.15% off the targeted high while a plunge would see the stock lose 1415.15% from current levels.

Cleveland BioLabs, Inc. (CBLI) estimates and forecasts

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -19% over the past 5 years. Earnings growth for 2020 is a modest +26.7% while over the next 5 years, the company’s earnings are expected to increase by 0%.